Stroke prevention with lipid-lowering therapy

Expert Review of Neurotherapeutics

Volumn 4, Issue 2, 2004, Pages 233-239

  Piechowski Jozwiak, Bartlomiej ^a   Bogousslavsky, Julien ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Lipid; Prevention; Stroke; Therapy

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; C REACTIVE PROTEIN; CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FIBRINOGEN; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; OBESITY; PHYSICAL ACTIVITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SECONDARY PREVENTION; SMOKING; STROKE; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; HUMANS; HYPERLIPIDEMIAS; RISK FACTORS;

EID: 1542344423     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.2.233     Document Type: Review

References (45)

1. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor Type 1. Circulation 85(5), 1888-1893 (1992).
2. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99(24), 3125-3131 (1999).
3. Staels B, Koenig W, Habib A et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PRARγ activators. Nature 393(6687), 790-793 (1998).
4. Seiler C, Suter TM, Hess OM. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J. Am. Coll. Cardiol. 26(7), 1615-1622 (1995).
5. Borghi C, Veronesi M, Prandin MG, Dormi A, Ambrosioni E. Statins and blood pressure regulation. Curr. Hypertens. Rep. 3(4), 281-288 (2001).
6. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 6, 1399-1402 (2000).
7. Rosemon TS, Tangnez CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279(20), 1643-1650 (1998).
8. Vaughan CJ, Dalanty N. Neuroprotective properties of statins in cerebral ischaemia and stroke. Stroke 30, 1969-1973 (1999).
9. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Eng. J. Med. 344, 1959-1965 (2001).
10. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipil lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256), 577-581 (2001).
11. Castelli WP, Anderson Y, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemiol. 2(1-2), 23-28 (1992). Gold standard epidemiological study.
12. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16(2), 434-444(1993). Gold standard epidemiological study.
13. Emond MJ, Zareba W. Prognostic value of cholesterol in women of different ages. J. Women Health (6), 295-307 (1997).
14. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 346, 1647-1653 (1995). A combined analysis of cohort trials on cholesterol levels and stroke rate.
15. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and 6-year mortality from stroke in 350,977 men screened for the multiple risk factors interventional trial. N. Eng. J. Med. 320, 904-910 (1989). Longitudinal study of 350,000 men screened for multiple risk factors.
16. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in eastern Asian. Lancet 352, 1801-1807 (1998). Systematic review of 13 Asian cohorts (125,000 subjects).
17. Lindenstrom E, Boysen G, Nyobe J. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. Br. Med. J. 309, 11-15 (1994).
18. Hachinski V, Graffagnino C, Beaudry M et al. Lipids and stroke: a paradox resolved. Arch. Neurol. 53(4), 303-308 (1996).
19. Tanne D, Koren-Morag N, Graff E, Goldbourt U. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) registry: high triglycerides constitute an independent risk factor. Circulation 104(24), 2892-2897 (2001).
20. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease and death. The Framingham Study. Arch. Intern. Med. 141(9), 1128-1131 (1981).
21. Njolstad I, Arnesen E, Lund-Larsen PG. Body height, cardiovascular risk factors and risk of stroke in middle-aged men and women. A 14-year follow-up of the Finnmark Study. Circulation 94(11), 2877-2882 (1996).
22. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Eng. J. Med. 335(14), 1001-1009 (1996). Randomized trial on secondary coronary prevention.
23. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N. Eng. J. Med. 339, 1349-1357 (1998). Randomized trial on secondary coronary prevention.
24. Plehn JF, Davis BR, Sacks FM et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99(2), 216-223 (1999). Randomized trial on secondary coronary prevention.
25. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N. Eng. J. Med. 339(19), 1349-1357 (1998). Randomized trial on secondary coronary prevention.
26. White HD, Simes RJ, Anderson NE et al. Pravastatin therapy and the risk of stroke. N. Eng. J. Med. 343(5), 317-326 (2000).
27. LIPD (Long-term Intervention with Pravastatin in Ischaemic Disease) Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359(9315), 1379-1387 (2002).
28. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Eng. J. Med. 333(20), 1301-1307 (1995). Randomized trial on primary coronary prevention.
29. ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: The Antihypertensive and lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLBAT-LLT). JAMA 288(23), 2998-3007 (2002).
30. Shepherd J, Blauw GJ, Murphy MB et al. Prospective study of pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346), 1623-1630 (2002). Randomized trial on primary and secondary prevention of cardiac and brain ischemic complications.
31. Wierzbicki AS, Mikhailidis DP, Reynolds TM. More on PROSPER. Lancet 361(9363), 1135-1136 (2003).
32. Byington RP, Davis BR, Plehn JF et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 10(3), 387-392 (2001). Summary of pravastatin trials.
33. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383-1389 (1994). Randomized trial on secondary coronary prevention and primary stroke prevention in high-risk patients.
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (9326), 7-22 (2002).
35. Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr. Med. Res. Opin. 18(4), 220-228 (2002).
36. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102, 21-27 (2000).
37. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Eng. J. Med. 341(6), 410-418 (1999).
38. Arkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 119(2), 136-145 (1993). First systematic review of lipid lowering strategies.
39. Di Mascio R, Marchioli R, Tognoni G. Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovasc. Dis. 10(2), 85-92 (2000). A systematic review of lipid lowering strategies.
40. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern. Med. 163(6), 669-676 (2003). Most recent systematic review of lipid-lowering strategies.
41. Manktelow B, Gillies C, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. In: The Cocbrane Library. Issue Four. John Wiley & Sons Ltd, Chichester, UK (2003). Cochrane systematic review of lipid-lowering strategies in cardiovascular prevention.
42. Amarenco P, Bogousslavsky J, Callahan AS et al. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovax. Dis. 16(4), 389-395 (2003).
43. Goldstein L, Amarenco P, Bogousslavsky J et al. Statins for secondary stroke prevention in patients without known coronary heart disease: the jury is still out. Cerebrovasc. Dis. (2004) (In Press).
44. Aminbakhsh A, Mancini GB. Carotid intima-media thickness measurements: what defines an abnormality? A systematic review. Clin. Invest. Med. 22(4), 149-157 (1999).
45. Hacke W, Kaste M, Bogousslavsky J et al. European Stroke Initiative Executive Committee and the EUSI Writing Committee. European Stroke Initiative Recommendations for Stroke Management - update 2003. Cerebrovasc. Dis. 16(4), 311-337 (2003). European recommendations for stroke treatment.